Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Stu
Clinical Professor, Pete and Carolyn Newsome Urologic Oncology Professorship, David A. Cofrin Endowed Chair Of Urologic Oncology, and Associate Director Of Clinical Research, Uf Health Cancer Center
